

BIOCON GROUP

FINANCIALS

Q1 FY 2006 vs Q1 FY 2005

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT
(Rs. crores)

Particulars	Q1 FY 2006	Q1 FY 2005	Variance Q1 FY 06 vs Q1 FY 05	Full Year ended March 31, 2005
<u>INCOME</u>				
Sales-Biopharmaceuticals	135	140	-3%	557
Sales- Enzymes	20	20	-3%	90
Contract research	19	14	35%	66
Total Sales	174	174	0%	713
Other income	2	4		15
Total Income	176	178	-1%	728
<u>EXPENDITURE</u>				
Manufacturing & other exp	124	121	2%	489
PBIDT /EBIDTA	52	57	-9%	239
Interest and finance charges	0	0		2
PBDT	52	57	-7%	237
Depreciation	7	5		22
PBT	45	52	-14%	215
Taxes	7	3		18
PROFIT FOR THE PERIOD	38	49	-20%	197
Add/(loss): Minority interest	1	0		1
NET PROFIT (PAT)	39	49	-20%	198
EPS on issued capital– (Rs)	3.9	4.9	-20%	19.8

NOTE: The figures are rounded off to nearest crores, percentages are based on absolute numbers

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		
Particulars	As at 30-Jun-05	As at 31-Mar-05
<u>SOURCES OF FUNDS</u>		
Share Capital	50	50
Reserves & Surplus	729	691
Total Shareholder's Funds	779	741
Minority interest	1	1
Deferred Tax Liability	23	23
Secured Loans	1	49
Unsecured Loans	29	27
Total Loan Funds	30	76
Total	833	841
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	630	578
Investments	154	235
Inventories	75	74
Sundry debtors	198	183
Cash and bank balances	7	3
Loans and advances	13	17
Total Current Assets, Loans & Advances	293	277
Less: Current liabilities and provisions	244	249
Net Current assets	49	28
Total	833	841

BIOCON LIMITED (CONSOLIDATED)		
STATEMENT OF CASH FLOWS		<i>(Rs. crores)</i>
Particulars	Quarter ended June 30, 2005	Full Year ended March 31, 2005
<u>I. Cash Flow from Operating Activities</u>		
Net profit before tax	45	215
Less/Add: non-cash items/ items required separately		
Depreciation	7	22
Others	(1)	(10)
Changes in working capital and other provisions	(1)	(43)
Cash generated from operations	50	184
Tax paid (net of refunds)	(2)	(12)
Net Cash provided by operating activities	48	172
<u>II. Cash Flow from Investing Activities</u>		
Fixed Assets	(82)	(285)
Interest / dividend received	2	13
Investments	81	(213)
Net cash used for investing activities	1	(485)
<u>III. Cash Flows from Financing Activities</u>		
Proceeds from issuance of share capital (net of expenses)	0	0
Borrowings and other financing activities	(46)	(2)
Net Cash provided/(used) for financing activities	(46)	(2)
<u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u>		
	3	(315)
<u>V. Cash & Cash Eq. at the beginning of the year</u>	3	318
<u>VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST ACQUIRED DURING THE YEAR</u>	1	0
<u>VI. Cash and Cash Eq. at the end of the year (IV+V)</u>	7	3